{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:51:54Z","timestamp":1793875914409,"version":"4.7.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cell surface expression levels of GPRC5D, an orphan G protein\u2013coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic strategies. The novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, effectively kills GPRC5D+ MM cell lines in the presence of T cells from both healthy donors or heavily pretreated MM patients. In addition, talquetamab has potent anti-MM activity in bone marrow (BM) samples from 45 patients, including those with high-risk cytogenetic aberrations. There was no difference in talquetamab-mediated killing of MM cells from newly diagnosed, daratumumab-na\u00efve relapsed\/refractory (median of 3 prior therapies), and daratumumab-refractory (median of 6 prior therapies) MM patients. Tumor cell lysis was accompanied by T-cell activation and degranulation, as well as production of pro-inflammatory cytokines. High levels of GPRC5D and high effector:target ratio were associated with improved talquetamab-mediated lysis of MM cells, whereas an increased proportion of T cells expressing PD-1 or HLA-DR, and elevated regulatory T-cell (Treg) counts were associated with suboptimal killing. In cell line experiments, addition of Tregs to effector cells decreased MM cell lysis. Direct contact with bone marrow stromal cells also impaired the efficacy of talquetamab. Combination therapy with daratumumab or pomalidomide enhanced talquetamab-mediated lysis of primary MM cells in an additive fashion. In conclusion, we show that the GPRC5D-targeting T-cell redirecting bispecific antibody talquetamab is a promising novel antimyeloma agent. These results provide the preclinical rationale for ongoing studies with talquetamab in relapsed\/refractory MM.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003805","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T15:33:27Z","timestamp":1619192007000},"page":"2196-2215","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":178,"title":["Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-207X","authenticated-orcid":false,"given":"Christie P. M.","family":"Verkleij","sequence":"first","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6284-109X","authenticated-orcid":false,"given":"Marloes E. C.","family":"Broekmans","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"van Duin","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine A.","family":"Frerichs","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3703-1762","authenticated-orcid":false,"given":"Rowan","family":"Kuiper","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-1762","authenticated-orcid":false,"given":"A. Vera","family":"de Jonge","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3677-4804","authenticated-orcid":false,"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Myeloma Group, The Institute of Cancer Research, London, United Kingdom;"},{"name":"Department of Hematology, The Royal Marsden Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Morgan","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Axel","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengasamy","family":"Boominathan","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Sendecki","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wong","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca I.","family":"Verona","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-4591","authenticated-orcid":false,"suffix":"III","given":"Homer C.","family":"Adams","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuna","family":"Mutis","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"issue":"1","key":"2021042315323036600_B1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2021042315323036600_B2","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"2021042315323036600_B3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"2021042315323036600_B4","author":"Lonial","year":"2019"},{"issue":"2","key":"2021042315323036600_B5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"2021042315323036600_B6","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"18","key":"2021042315323036600_B7","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2021042315323036600_B8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021042315323036600_B9","first-page":"2203","article-title":"Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume-title":"Clin Cancer Res","author":"Frerichs","year":"2020"},{"key":"2021042315323036600_B10","doi-asserted-by":"crossref","first-page":"Abstract 143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial [abstract]","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"2021042315323036600_B11","doi-asserted-by":"crossref","first-page":"Abstract 577","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: a phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R MM) [abstract]","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"key":"2021042315323036600_B12","doi-asserted-by":"crossref","first-page":"Abstract 27","DOI":"10.1182\/blood-2020-138831","article-title":"Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and\/or refractory multiple myeloma (RRMM) [abstract]","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"issue":"13","key":"2021042315323036600_B13","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2021042315323036600_B14","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"7750","key":"2021042315323036600_B15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"6","key":"2021042315323036600_B16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","article-title":"GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells","volume":"18","author":"Cohen","year":"2013","journal-title":"Hematology"},{"issue":"3","key":"2021042315323036600_B17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-4781(01)00197-X","article-title":"Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D","volume":"1518","author":"Br\u00e4uner-Osborne","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"2021042315323036600_B18","first-page":"3099","article-title":"GPRC5D is a cell surface plasma cell marker whose expression is high in myeloma cells and reduced following coculture with osteoclasts","volume-title":"Blood","author":"Venkateshaiah","year":"2013"},{"issue":"485","key":"2021042315323036600_B19","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"9","key":"2021042315323036600_B20","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2021042315323036600_B21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"2021042315323036600_B22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2021042315323036600_B23","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"2021042315323036600_B24","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.3324\/haematol.2015.139667","article-title":"Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance","volume":"101","author":"de Haart","year":"2016","journal-title":"Haematologica"},{"issue":"20","key":"2021042315323036600_B25","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-12-3676","article-title":"Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance","volume":"19","author":"de Haart","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021042315323036600_B26","doi-asserted-by":"crossref","first-page":"Abstract 137","DOI":"10.1182\/blood-2019-125818","article-title":"The impact and modulation of microenvironment-induced immune resistance against CAR T cell and antibody treatments in multiple myeloma [abstract]","volume":"134","author":"Holthof","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2021042315323036600_B27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"15","key":"2021042315323036600_B28","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2021042315323036600_B29","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"2021042315323036600_B30","doi-asserted-by":"crossref","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"2021042315323036600_B31","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections","volume":"47","author":"Sch\u00fctt","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2021042315323036600_B32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3816\/CLML.2010.n.019","article-title":"Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib","volume":"10","author":"Heider","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021042315323036600_B33","first-page":"2376","article-title":"How I treat plasma cell leukemia","volume-title":"Blood","author":"van de Donk","year":"2012"},{"issue":"1","key":"2021042315323036600_B34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41467-020-14396-9","article-title":"Sexual-dimorphism in human immune system aging","volume":"11","author":"M\u00e1rquez","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"2021042315323036600_B35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/2326-6066.CIR-13-0049","article-title":"Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody","volume":"1","author":"Choi","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2021042315323036600_B36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.immuni.2004.09.002","article-title":"Human T regulatory cells can use the perforin pathway to cause autologous target cell death","volume":"21","author":"Grossman","year":"2004","journal-title":"Immunity"},{"issue":"10","key":"2021042315323036600_B37","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2021042315323036600_B38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"74","key":"2021042315323036600_B39","doi-asserted-by":"crossref","first-page":"34009","DOI":"10.18632\/oncotarget.26131","article-title":"Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients","volume":"9","author":"Franssen","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"2021042315323036600_B40","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"issue":"17","key":"2021042315323036600_B41","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models [published correction appears in Blood Adv. 2020;4(17):4195-4207]","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2021042315323036600_B42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmet.2017.10.006","article-title":"CD38-NAD+axis regulates immunotherapeutic anti-tumor T cell response","volume":"27","author":"Chatterjee","year":"2018","journal-title":"Cell Metab"},{"key":"2021042315323036600_B43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2020-133873","article-title":"A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and\/or refractory multiple myeloma (RRMM)","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/8\/2196\/1805797\/advancesadv2020003805.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/8\/2196\/1805797\/advancesadv2020003805.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T15:33:53Z","timestamp":1619192033000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/8\/2196\/475794\/Preclinical-activity-and-determinants-of-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003805","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]}}}